Report of the 2014 APhA-ASP Resolutions Committee
Appendix A
2014 Proposed Resolution Ranking & Feedback
TRANSPARENCY AND ACCESSIBILITY OF PROPOSED RESOLUTIONS
The following recommendations were made during the fall 2013 APhA-ASP Midyear Regional Meetings
to the APhA-ASP Resolutions Committee:
Location:
Action:
Region 3 MRM in Birmingham, AL – Sunday, November 3, 2013
Improve/Amend APhA-ASP Policy Process
RIII.4 - Resolution Process Transparency and Accessibility
APhA-ASP strongly encourages an increase in the transparency and accessibility of the policy
process.
1. APhA-ASP supports creating official methods for constructive comments and feedback to be
made available for chapters following the decisions and actions of the Resolutions
Committee, which could aid chapters in the development of future resolutions.
2. APhA-ASP affirms that all chapters across the country should have access to all proposed
resolutions and aforementioned feedback to further encourage communication and
transparency between regions and their policy ideas.
The APhA-ASP Resolutions Committee and the APhA-ASP Policy Standing Committee discussed the
proposed idea and felt that it was important to provide some level of feedback within the parameters of
the Committee’s time and resources. If you have any questions or concerns, please contact your
Regional Delegate.
FEEDBACK TO REGIONS
While reviewing each of the proposed resolutions, the APhA-ASP Resolutions Committee develops a
ranked list of policy proposals, and after 3 rounds of discussion, the Committee develops a consensus on
the top issues. Within the full list of proposed resolutions, the Committee has provided a reason code as
well as a percentage of where the resolution ranked within the overall list.
Reason Codes:
1 – Proposed Resolution is a great idea and received serious consideration and discussion.
2 – Proposed Resolution is a good idea, but not a priority for APhA-ASP at this time.
3 – Proposed Resolution is too similar to existing active and/or inactive resolutions.
4 – Proposed Resolution is too specific or too narrow of scope for APhA-ASP to address nationally.
5 – Proposed Resolution was not viewed as priority due to existing initiatives related to that issue.
6 – Proposed Resolution is in conflict with current APhA or APhA-ASP policy.
Percentage Rank:
A – Proposed Resolution ranked within the top 1% - 20% of all proposals.
B – Proposed Resolution ranked within the 21% - 40% of all proposals.
C – Proposed Resolution ranked within the 41% - 60% of all proposals.
D – Proposed Resolution ranked within the 61% - 80% of all proposals.
E – Proposed Resolution ranked within the bottom 81% - 100% of all proposals.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 2 of 13
HOW TO READ THE LIST OF PROPOSED RESOLUTIONS
During the deliberations of the APhA-ASP Resolutions Committee Meetings, the Committee needs a way
to organize proposed resolutions based upon the current APhA-ASP Policy Book by issue, and then also
group similar ideas passed among all of the Midyear Regional Meeting Closing Business Sessions. The
following method has been developed to organize and rank the proposed resolutions.
Example of (Past) Issue:
(27.RII.3) = ISSUE NUMBER XX, REGION 2, PASSED POLICY #3
27.RII.3 - Recycling and Use of Energy Efficient Practices
APhA-ASP proposes that the practice of pharmacy be carried out under environmentally
conscious conditions, unless such conditions would be detrimental to the health and safety of
patients. This includes but is not limited to the use of renewable resources, the practices of
recycling, proper storage and disposal of harmful substances, and the use of energy efficient
practices and procedures.
Issue Number:
27. = “ISSUE NUMBER”
Please note that there may be multiple proposed policies under a specific issue
number. Rankings are provided for the “issue number” only and not a specific
proposed policy.
Roman Numerals:
RI = REGION 1 RII = REGION 2
RIII = REGION 3 RIV = REGION 4
RV = REGION 5 RVI = REGION 6
RVII = REGION 7
RVIII = REGION 8
Passed Policy:
3. = “PASSED POLICY”
The order in which the proposed resolutions were passed during the Closing
Business Session at the MRM.
Policy Book:
IV. CURRICULUM
IV e. CURRICULUM - SPECIFIC COURSES
Corresponds to the policy heading found in the APhA-ASP Policy Book. Please
review the policy book as you are reviewing the proposed polices.
Rank & Percentage:
Examples: 1/A or 5/E
See the above Feedback to Regions section of this document.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 3 of 13
APhA Academy of Student Pharmacists
2014 Resolutions Committee – Appendix A
PROPOSED POLICIES SORTED BY ISSUE
Please note that the following proposed resolutions from the fall 2013 Midyear Regional Meetings were
forwarded directly to the APhA-ASP Policy Standing Committee and are not found in the list below:



RIII.4 - Resolution Process Transparency and Accessibility
RIV.2 - OTC+
RVI.10 - Proposed Amendment to 2008.2 - Health Literacy
All of the Reports of the APhA-ASP Midyear Regional Meeting Closing Business Sessions can be found on
the APhA-ASP House of Delegates Web page on pharmacist.com. Please contact your Regional Delegate
if you have any questions or concerns.
II. COLLABORATIVE AGREEMENTS
II b. COLLABORATION WITH OTHER HEALTH PROFESSIONALS
1.RI.8 - Specialty Drugs -- 2/C
APhA-ASP supports the creation of a formal definition of “specialty drug” as defined by a committee
formed by a multidisciplinary team of pharmacists, physicians, insurance representatives, and nurses.
1.RIII.7 - Specialty Pharmacy Awareness and NASP Growth -- 4/C
APhA-ASP supports increasing public and physician awareness of the unique patient care services
offered by specialty pharmacies. APhA-ASP simultaneously supports the growth of the NASP (National
Association of Specialty Pharmacy) in order to further this effort.
2.RIII.14 - Experiential and Didactic Curriculum to Develop Interprofessional Relations -- 3/A
APhA-ASP encourages Pharmacy Schools/College of Pharmacy to incorporate inter-professional
collaborative electives/experiences with other student healthcare disciplines within the pharmacy
school curriculum. The act of facilitating professional integration, communication, and quality of
healthcare can be done by:
1. Developing an experiential and didactic curriculum that prepares students for professional
interactions with healthcare professionals.
2. Enhance the didactic experience by integrating a M.D., D.O. and other health related disciplines into
the program.
3. Provide students with opportunities to experience various health care perspectives.
3.RVI.2 - Pharmacist Role in Sports Medicine -- 4/D
APhA-ASP actively encourages the inclusion of a team pharmacist in conjunction with a team physician
for collegiate and professional sports.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 4 of 13
III. CHEMICAL DEPENDENCY & HABIT FORMING SUBSTANCES
III a. PHARMACISTS RECOVERY NETWORK
4.RIII.1 - Addressing Alcohol and Drug Dependency in Pharmacists and Student Pharmacists -- 3/D
1. APhA-ASP reaffirms APhA-ASP resolution 1991.2 concerning addressing chemical dependency in
student pharmacists and encourages pharmacies, hospitals, and other employers of pharmacists to
develop protocols for handling situations where a pharmacist or student pharmacist is impaired by
alcohol or drug dependency.
2. APhA-ASP recommends that these protocols include as their first step the option for the impaired
pharmacist or student pharmacist to voluntarily seek inpatient treatment with long-term aftercare
programs.
3. APhA-ASP recommends that these protocols include notification of the state Board of Pharmacy as a
second step if voluntary treatment is denied and that notification of state law enforcement
authorities be retained as a last resort due to the lower likelihood of being able to reenter
professional practice once in recovery through this path.
IV. CURRICULUM
IV e. CURRICULUM - SPECIFIC COURSES
5.RI.5 - Integration of Advanced Safe Compounding Classes/Electives into the Curriculum -- 3/B
APhA-ASP encourages pharmacy schools to incorporate classes specific to compounding into the
curriculum in order to achieve uniformity in compounding education. This is not to undermine current
regulations held by states that require wet lab testing, but to bring the entire accrediting body to
baseline standards.
6.RII.8 - Licensure Preparation -- 2/E
APhA-ASP encourages schools of pharmacy to offer programs and assistance to prepare students for
licensure exams.
V. STUDENT / FACULTY / ADMINISTRATION
V b. STUDENT / FACULTY / ADMINISTRATION - FINANCIAL AID
7.RVII.2 – Deposits -- 2/E
APhA-ASP supports the establishment of a set date before which schools of pharmacy cannot require
students to commit a deposit to that institution.
V. STUDENT / FACULTY / ADMINISTRATION
V d. STUDENT / FACULTY / ADMINISTRATION - FACULTY REQUIREMENTS
8.RVIII.1 - Expanding the role of student pharmacists through receiving reimbursement for MTM
services -- 5/E
APhA-ASP asks for reimbursement for pharmacists precepting student pharmacists providing MTM
services.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 5 of 13
IX. POST GRADUATE EDUCATION / CONTINUING EDUCATION
9.RIII.10 - Creation of Additional Ambulatory Care Residencies -- 3/D
APhA-ASP encourages the creation of additional residency sites and positions especially those with an
emphasis in ambulatory care.
10.RVIII.8 - CPR Certification for Pharmacists -- 3/E
APhA‐ASP encourages pharmacists and student pharmacists to both obtain and maintain certification in
cardiopulmonary resuscitation (CPR) and Basic Life Safety, while concurrently attaining proficiency with
the proper use of an AED device, practical airway management, and effective teamwork during code
situations.
X. LEGISLATIVE RECOMMENDATIONS / POLITICAL ACTION
X a/b. LEG REC / POLITICAL ACTION – CALL FOR LEGISLATION / REGULATION / POLITICAL ACTION
11.RI.2 - Drug Importation -- 3/D
APhA-ASP opposes any state legislation that compromises patient safety or privacy, endorses the
unlicensed practice of pharmacy, or takes away a patient’s right to legal recourse for harm resulting
from unsafe prescription drugs.
12.RI.3 - National Registry -- 3/A
1. APhA-ASP reaffirms APhA-ASP Resolution 2008.6 and further recommends the expansion of the
national registry mentioned in the resolution to be all-inclusive and embody all controlled and noncontrolled substance prescription items which each patient is using.
2. APhA-ASP suggests the name of this registry to be the National Patient Profile (NPP) and also
encourages that the NPP be accessible to all licensed healthcare professionals in all 50 states in an
effort to provide continuous patient care in any unavoidable circumstances which prevent the patient
from using only one pharmacy.
12.RIII.2 - Prescription Monitoring Program Standardization and Nationwide Access -- 1/A
1. APhA-ASP supports the development and adoption of a nationally-accepted standardized format for
the submission and maintenance of patient identification information for all state-administered
Prescription Monitoring Programs (PMP).
2. APhA-ASP reaffirms that state-administered PMP registries should be accessible to all healthcare
professionals involved in the care of patients.
3. APhA-ASP supports the interconnectivity of all states with PMP’s through the establishment of
agreements between states and through participation in nationally-recognized PMP interconnectivity
programs, such as National Association of Boards of Pharmacy PMP InterConnect program, to
support a more complete and comprehensive framework of access to state-administered PMP’s.
12.RIII.8 - National Pseudoephedrine Database -- 3/A
APhA-ASP encourages all states to actively participate in the National Precursor Log Exchange, a realtime pseudoephedrine database to monitor and regulate the sales of pseudoephedrine products.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 6 of 13
12.RIV.3 - Student Pharmacist Inclusion in Prescription Drug Monitoring Programs -- 1/A
1. APhA-ASP encourages increased pharmacist utilization of PDMP.
2. APhA-ASP encourages individual state prescription drug monitoring programs to allow access to
student pharmacists so as to further the ultimate goal of preventing improper use of controlled
substance medications
3. APhA-ASP encourages increasing awareness among other health care professionals that such
programs exist.
12.RIV. 4 - Requirement of Documentation for Controlled Medications -- 1/A
APhA-ASP supports and encourages the requirement of all ambulatory pharmacies to document
personal identification when dispensing controlled prescription drugs.
13.RV.5 - National Pain Treatment Agreement Database -- 2/B
APhA-ASP advocates for the implementation of an interdisciplinary, national database of chronic pain
treatment agreements to protect patients from dependency and discourage diversion as well as ensure
all health care providers are aware of a patient’s current agreement.
14.RII.1 - Use of Diagnosis Codes on Prescriptions and Medication Labeling -- 3/A
APhA-ASP encourages the requirement of diagnosis codes, specifically ICD-9, to be included on
prescriptions, such that pharmacists may utilize clinical knowledge in making professional decisions
when dispensing and verifying medications.
14.RII.5 - Standardized Prescription Medication Labels -- 3/A
APhA-ASP encourages adoption of the United States Pharmacopeial (USP) standards for universal
formatting on prescription medication labels. Furthermore, APhA-ASP supports the inclusion of a field
for designating medication indication, as diagnosed by the prescriber, on both the prescription (written,
electronic, oral) and [at the patient's request] on the USP-formatted prescription label.
14.RVI.3 - Pharmacy Inquiries -- 3/A
APhA-ASP encourages all pharmacists and student pharmacists to continue to work with prescribers in a
collaborative and collegial manner in order to insure optimal patient care.
1. APhA-ASP resolves that it is appropriate for pharmacists to verify the medical rationale behind
prescriptions, diagnoses, and treatment plans.
2. APhA-ASP supports the notion that pharmacists must be able to take the necessary action through
their diligent efforts and judgment to uphold their responsibility of ensuring that prescriptions are for
legitimate medical use, especially in light of the prescription drug abuse epidemic, in order that
patients obtain the most appropriate medication for their individual needs.
3. APhA-ASP further resolves that the future of healthcare, in order to optimize outcomes and improve
patient care, must be one where all relevant medical information, including indications and rationale
for drug treatments, should be made available to all pertinent health care providers.
14.RVI.9 - Pharmacist Access to Diagnosis Codes on Electronic Prescriptions -- 3/A
APhA-ASP supports a position of allowing diagnosis codes to be viewable to pharmacists on every
electronic prescription in order to help facilitate efficient patient care.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 7 of 13
15.RII.7 - Used Prescription Vial Recycling Program Advocacy -- 3/B
APhA-ASP encourages pharmacists and student pharmacists to advocate for the creation of a
prescription vial recycling program, while maintaining HIPAA regulations, to decrease solid waste impact
on landfills and sustain the global environment.
16.RII.9 - Prescription Content -- 2/C
APhA-ASP encourages the inclusion of the prescriber’s NPI number on all written and electronic
prescriptions that will be billed to third-parties.
17.RV.3 - Needles and Sharps Collection Programs -- 3/D
1. APhA‐ASP supports state and federal legislative efforts, laws, and regulations that encourage
pharmacies as well as hospitals, clinics, and other healthcare facilities to take back used needles,
lancets, and syringes through a process that minimizes liability and financial burden to all
stakeholders and maintains the confidentiality of those who utilize these programs.
2. APhA-ASP encourages pharmacies as well as hospitals, clinics, and other healthcare facilities to
develop and implement free, confidential collection programs for needles, lancets, and syringes used
outside of the healthcare setting.
18.RVI.7 - Limited Population Antibacterial Drug Approval -- 2/B
1. APhA-ASP supports the implementation of an expedited approval process for Limited Population
Antibacterial Drugs (LPADs).
2. APhA-ASP encourages extensive monitoring of clinical outcomes in patients treated with LPADs by
the FDA, drug companies, and other stakeholders.
19.RVII.7 - Pharmacist Dispensed Third Class of Drugs -- 3/A
APhA-ASP supports the development of a standardized course which certifies pharmacists to assess
minor ailments seen in the community pharmacy and prescribe indicated medications based on a welldefined treatment algorithm and specific inclusion and exclusion criteria developed through
interdisciplinary collaboration between pharmacy and medicine.
19.RVIII.7 - Furnishing Travel Medications -- 1/A
APhA-ASP encourages the expansion of a pharmacists' role to include the ability to furnish and consult
on travel medications.
19.RII.2 - Anaphylaxis Protocol -- 1/A
APhA-ASP supports pharmacists being able to administer epinephrine (i.e. EpiPen) to a patient
experiencing anaphylaxis without requiring direct prescriber authority, pursuant to a protocol
agreement with a prescriber.
19.RII.4 - Prescription of Nicotine Replacement Therapy and Pharmacological Smoking Cessation Aids
by a Pharmacist -- 5/A
APhA‐ASP encourages APhA and other professional pharmacy organizations to support legislation
allowing pharmacists to prescribe purely nicotine replacement therapy.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 8 of 13
20.RVIII.4 - Biological Drugs and Biosimilars -- 2/C
1. APhA-ASP encourages the FDA to have effective and efficient oversight of the approval of biosimilars
and to require appropriate analytical data, non-clinical data, clinical studies, and necessary
pharmacovigilance plans from the manufacturer to ensure no clinical difference in safety and
efficacy.
2. APhA-ASP encourages the FDA to create appropriate guidelines regarding which biosimilars may be
safely and therapeutically interchangeable with its reference biological drug.
3. APhA-ASP encourages the development of an appropriate method of differentiating the biosimilar
from its reference biological drug to aid in identification and traceability of the drug product.
4. APhA-ASP encourages pharmacy students and pharmacists to have knowledge of biological drugs and
biosimilars and to have the ability to convey relevant differences between them to patients.
20.RV.2 - Biosimilars -- 2/C
APhA-ASP encourages third-party payors to institute policies and update their formularies to include
biosimilar medications and for states to approve regulatory procedures regarding the approval of
biosimilars.
XI. OTC PRODUCTS
21.RVIII.10 - Placement of Over-the-Counter Emergency Contraceptives -- 3/C
APhA-ASP encourages community pharmacies to display over-the-counter emergency contraception in
the OTC aisle.
XIII. PATIENT EDUCATION
22.RIII.12 - Increasing Patient Adherence -- 5/D
APhA-ASP supports pharmacists use of strategies to improve patient adherence including but not limited
to considering the health literacy of each individual, by providing user-friendly medication schedules
using medication synchronizations, and providing a support system.
22.RIV.5 - Medication Synchronization -- 2/D
APhA-ASP encourages the further development and implementation of medication synchronization
models to be used at the discretion of the pharmacist in order to increase patient adherence and
medication management.
23.RVI.4 - Education of Healthcare Reform -- 3/B
APhA-ASP supports the involvement of pharmacists and student pharmacists in the education of health
care professionals, patients, and the public to achieve a more comprehensive understanding of health
care reform to safeguard patients and improve their care and treatment.
24.RVI.5 - Inclusion of Non-Pharmacological Recommendations in Counseling Sessions -- 2/D
APhA-ASP encourages all pharmacists and student pharmacists to include non-pharmacological
recommendations, such as diet, exercise, and other lifestyle modifications, in all medication counseling
sessions.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 9 of 13
25.RVI.8 - Medication Therapy Management Promotion -- 3/B
APhA-ASP encourages pharmacist and student pharmacist to promote availability of Medication Therapy
Management (MTM) services to all patients who the pharmacist believes will receive benefit from these
services. Pharmacist should utilize clinical judgment to determine patients with the greater need within
their specific communities. Pharmacists should develop criteria similar to those established by CMS to
effectively identify these patients.
26.RVII.6 - HIV PrEP (Pre - Exposure Prophylaxis) -- 3/E
APhA-ASP encourages all pharmacists to inform patients who may be at high risk for HIV to speak with
their provider about access to HIV PrEP (Pre – Exposure Prophylaxis).
XVI. PHARMACEUTICAL CARE / PATIENT CARE
27.RI.1 - Point of Care Testing -- 1/3/A
APhA-ASP recommends allowing student pharmacists and licensed pharmacist to perform point of care
testing, including but not limited to blood glucose, cholesterol, and creatinine.
27.RVIII.9 - Rapid HIV testing in community pharmacies -- 1/A
APhA-ASP supports the advent of rapid HIV testing at community pharmacies to increase accessibility to
HIV testing, connect HIV positive patients with specialists, and help stop the spread of HIV.
27.RIII.9 - Pharmacogenomic Testing Promotes Individualized Treatment Plans through an
Interdisciplinary Approach or Collaborative Practice Agreement -- 1/A
APhA-ASP supports pharmacogenomics testing as a clinical service provided by pharmacists and the
interpretation of the result to the providers and the patients by pharmacists, in order to provide
individualized treatment plans to patients.
28.RI.4 - Pharmacist-Directed Anticoagulation Services (PDAS) -- 1/B
APhA-ASP proposes that Pharmacist-Directed Anticoagulation Services (PDAS) become essential as a
standard amongst all anticoagulation clinics and units in the nation. APhA-ASP believes that the quality
of care for patients should be supplied by the most appropriate health care provider, and that certified
pharmacists should be in control of anticoagulation monitoring, dose adjusting, and patient education.
29.RVII.5 - Improving patient understanding of vaccines and vaccine preventable diseases -- 3/C
APhA-ASP encourages pharmacists and student pharmacists to take an active role in public vaccination
programs and to assist patients in understanding the value of vaccination.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 10 of 13
30.RV.4 - Increasing Access to Pharmacists in Rural Areas -- 1/A
APhA-ASP encourages the growth and sustainment of rural pharmacies and other health care systems
by providing incentives including, but not limited to reimbursement systems, to promote pharmacists to
practice in rural areas.
30.RVI.1 - Patient Care in Rural/Underserved Communities -- 1/A
APhA-ASP encourages pharmacists and student pharmacists to reach out to rural and/or underserved
communities, and provide general health screenings that would otherwise not be available.
30.RIII.3 - Empowering Pharmacists with the Legal Capacity to Provide Pharmacy Services through
Mobile Healthcare Clinics for Vulnerable and Underserved Populations -- 1/A
APhA-ASP supports advocacy efforts and legislation that will empower pharmacists with the legal
capacity to provide pharmacy services, including, but not limited to, the dispensing of medication,
education of patients, and management of chronic diseases, to those vulnerable and underserved
populations found in “pharmacy deserts” through mobile clinics.
31.RIII.5 - Pharmacists role in the transition of care of patients -- 3/5/A
APhA-ASP supports hospitals developing a process where pharmacists and student pharmacists are
utilized in the transition of care of patients including discharge counseling and post-discharge follow ups
to reduce readmission rates of chronic disease states.
31.RIV.1 - Pharmacist Inclusion in the Transition of Care Model -- 3/A
1. APhA-ASP supports and encourages the participation and inclusion of the pharmacist in previously
established Transition of Care models such as the model laid out by CMS. The role of the Pharmacist
will include and is not limited to, providing a medication review, therapy overview, and other services
for a recently hospital discharged patient to reduce the risk of readmission from a preventable
complication.
2. APhA-ASP supports and encourages the pharmacist be included as a “provider” in the
interdisciplinary team responsible for the Transition of Care and general patient care.
XVII. PHARMACY SUPPORT PERSONNEL
32.RVII.4 - Tech Check Tech Program -- 2/5/E
APhA‐ASP supports the promotion of the Tech-Check-Tech program which allows a technician’s orderfilling accuracy to be checked by another qualified technician, within the scope of non-discretionary
function, rather than a pharmacist in an institutionalized setting.
XVIII. SAFETY
33.RII.6 - Greater Involvement of Pharmacists in Post-marketing Surveillance -- 2/D
APhA-ASP encourages pharmacists and student pharmacists to become more actively involved in postmarketing surveillance practices to optimize safety and efficacy of drug therapy.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 11 of 13
34.RIII.6 - Proper Medication Disposal and Take Back Programs -- 3/C
(Additions to Resolution 2012.3- Proper Medication Disposal and Drug Take‐Back Programs)
1. APhA-ASP encourages all schools and colleges of pharmacy to incorporate approved and effective
methods of medication disposal, as well as the possible negative impact that improper disposal could
have on our society and environment into the curriculum.
2. APhA-ASP encourages pharmacy schools and pharmacies to work with the proper authorities to
implement a medication drop-off where patients can drop off unused/expired medications for proper
disposal.
34.RV.1 - Expansion of drug-take away program -- 3/C
APhA-ASP moves to expand educational efforts the drug take- back program to include the safe disposal
of unused or expired controlled medications.
35.RIII.11 - Standardized Electronic Process to Capture Risk Evaluation Mitigation Strategies -- 5/C
APhA-ASP supports a standardized electronic process to capture approved Risk Evaluation and
Mitigation Strategies (REMS) program information to efficiently evaluate patient safety outcomes.
36.RIV.6 - Pharmacist DUR Authority -- 5/E
APhA-ASP encourages that only a pharmacist or student pharmacist on their Advanced Practice
Experience rotation will be the only one allowed to override a DUR error/rejection involving therapeutic
parameters in a community/retail setting.
37.RVIII.2 - Removal of automated dispensaries in physician’s office -- 1/3/D
APhA-ASP encourages the removal of automated prescription drug dispensaries in medical offices.
Current action should be made to remove such machines from physicians’ offices in order to protect the
safety of patients. Without the double check of the pharmacist the patient may be subjected to
medication errors, adverse drug events and a list of unforeseen complications.
38.RVIII.3 - Drug Safety -- 2/E
APhA-ASP supports greater oversight into foreign produced drugs to ensure safety and effectiveness of
drugs marketed in the United States.
39.RVIII.6 - Over-the-Counter Pediatric and Infant Liquid Dosing -- 5/C
APhA-ASP strongly supports the production of a single pediatrics and infants formulation for over-thecounter liquid formulas.
XIX. WORKPLACE ISSUES
40.RI.6 - Installing or Equipping Panic Buttons in Community Pharmacies -- 2/C
APhA-ASP supports the legislation that requires the installation or equipping of emergency panic
buttons in all community pharmacies to alert local police in times of emergency.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 12 of 13
41.RII.3 - Drive-Through Pharmacy -- 3/E
APhA-ASP discourages the use of drive-through pharmacies when picking up medications and supports
the imposition of limits on its practice through legislation and/or corporate policy.
42.RIII.13 - Staffing Requirements and Prescription Volume in Community Pharmacies -- 4/A
APhA-ASP encourages Boards of Pharmacy to enact rules that would limit a single pharmacist’s
workload, and require additional pharmacists staffing during times of high volume to allow for an
increased focus on patient-centered care in order to encourage that pharmacists are staffed in such a
way that maximizes patient safety and maintains pharmacists as the most accessible healthcare
practitioner in the country.
43.RVII.1 - Automated Pharmacy Systems Helping to Achieve Patient Safety -- 2/E
APhA-ASP encourages expanding the use of robotics and automated pharmacy operations in pharmacies
in order to increase patient safety by reducing or eliminating medication dispensing errors.
XXI. INSURANCE
44.RI.7 - Insurance Reimbursement for Vaccinations -- 2/3/A
APhA-ASP supports legislation that prohibits insurance companies denial of claims submitted for
pharmacist-administered vaccinations.
44.RVI.6 - In-Network Pharmacies Provide Preventative Health Services -- 2/3/A
APhA-ASP encourages all medical insurance companies to include all pharmacies in the reimbursement
networks for administering immunizations.
44.RVII.3 - Coverage of Immunizations -- 2/3/A
APhA-ASP encourages third party companies including Centers for Medicare and Medicaid Services
(CMS) to cover all prophylactic, seasonal, travel vaccines and PPD skin tests, which are eligible to be
given at community pharmacies by immunization certified pharmacists and student pharmacists.
45.RIII.15 - Patients Choice between Mail Order And Retail Pharmacy With No Penalty -- 3/B
APhA-ASP encourages a patients’ right to choose whether the patients’ medication(s) are filled through
either retail or mail-order pharmacy. APhA-ASP shall thus support third party payers to eliminate
differences in insurance benefit between in-network retail and mail order, nor will there be a penalty
associated with choosing a retail pharmacy over a mail-order pharmacy.
46.RVIII.5 - Regulation of Pharmacy Benefit Managers (PBMs) -- 2/B
APhA-ASP encourages legislation that would require pharmacy benefit managers (PBMs) to be
registered and regulated by the state board of pharmacy or the state insurance commission in each
state it chooses to do business in.
Report of the APhA-ASP Resolutions Committee – Appendix A – Page 13 of 13